- Allergan (AGN) ramps up its propaganda efforts in its battle to stay out the clutches of Valeant (VRX), saying that it expects EPS to increase 20-25% in 2015 and at an annual compound rate of 20% over five years.
- The company also forecasts "double-digit revenue growth" next year and over the coming five years.
- Meanwhile, Allergan has received over 500 letters from physician customers, patient advocacy groups and medical associations expressing support for the company following its rejection of Valeant's bid.
- Physicians have what Allergan describes as "grave concerns" about Valeant's proposal to slash Allergan's R&D expenditure by $1B a year. (PR)
- Previous coverage
at Nasdaq.com (Wed, 11:49AM)